Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Recent progress in diagnosis and treatment of Human African Trypanosomiasis has made the elimination of this disease a realistic target by 2030

3 Nov 2022

Abstract excerpt

Human African Trypanosomiasis (HAT) is caused by unicellular flagellated protozoan parasites of the genus Trypanosoma brucei. The subspecies T. b. gambiense is mainly responsible for mostly chronic anthroponotic infections in West- and Central Africa, accounting for roughly 95% of all HAT cases. Trypanosoma b. rhodesiense results in more acute zoonotic infections in East-Africa. Because HAT has a two-stage...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CRISPR and Genetic Engineering
Share to Insect symbiosis and bacterial influences
Share to Trypanosoma species research and implications

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 36405602
DOI: 10.3389/fmed.2022.1037094

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Recent progress in diagnosis and treatment of Human African Trypanosomiasis has made the elimination of this disease a realistic target by 2030PMID 36405602Read ↗

Trypa-NO! contributes to the elimination of gambiense human African trypanosomiasis by combining tsetse control with “screen, diagnose and treat” using innovative tools and strategiesSemantic proximity Read ↗

Contemporary and emerging strategies for eliminating human African trypanosomiasis due to <i>Trypanosoma brucei gambiense</i>: reviewSemantic proximity Read ↗

Fexinidazole as a new oral treatment for human African trypanosomiasis due to Trypanosoma brucei rhodesiense: a prospective, open-label, single-arm, phase 2–3, non-randomised studySemantic proximity Read ↗

SHERLOCK4HAT: A CRISPR-based tool kit for diagnosis of Human African TrypanosomiasisSemantic proximity Read ↗

A Brief Review of Drug Discovery Research for Human African TrypanosomiasisSemantic proximity Read ↗

New developments in human African trypanosomiasisSemantic proximity Read ↗

A next generation CRISPR diagnostic tool to survey drug resistance in Human African TrypanosomiasisSemantic proximity Read ↗

Human African trypanosomiasis: connecting parasite and host genetics.Semantic proximity Read ↗

A CRISPR-based diagnostic tool to survey drug resistance in human African trypanosomiasis.Semantic proximity Read ↗

Salivarian Trypanosomes Have Adopted Intricate Host-Pathogen Interaction Mechanisms That Ensure Survival in Plain Sight of the Adaptive Immune SystemSemantic proximity Read ↗

The current drug discovery landscape for trypanosomiasis and leishmaniasis: Challenges and strategies to identify drug targetsSemantic proximity Read ↗

Sensitivity and specificity of rapid diagnostic tests: HAT Bioline Abbott® 2.0 and HAT Sero K-Set CORIS® 2.0 in the detection of Human African TrypanosomiasisSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.